CLINICAL TRIALS PROFILE FOR STAUROSPORINE
✉ Email this page to a colleague
Clinical Trials for Staurosporine
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00001444 ↗ | A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms | Completed | National Cancer Institute (NCI) | Phase 1 | This is a dosage escalation study to estimate the maximum tolerated dose of staurosporine analogue UCN-01. Groups of 3 to 6 patients receive a 72-hours intravenous continuous infusions of UCN-01 from day 1 to day 4 of each cycle the first cycle only, and over 36-hours on subsequent cycles. The side effects are allowed to disappear for up to 28 days. This cycle is repeated after evaluations and follow-ups, which are every 4 weeks, as long as the patient benefits. |
| NCT00003289 ↗ | UCN-01 in Treating Patients With Advanced Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with advanced cancer that has not responded to previous treatment. |
| NCT00003289 ↗ | UCN-01 in Treating Patients With Advanced Cancer | Completed | Sidney Kimmel Comprehensive Cancer Center | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with advanced cancer that has not responded to previous treatment. |
| NCT00003289 ↗ | UCN-01 in Treating Patients With Advanced Cancer | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of UCN-01 in treating patients with advanced cancer that has not responded to previous treatment. |
| NCT00004059 ↗ | Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors | Completed | National Cancer Institute (NCI) | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. UCN-01 may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of fluorouracil plus UCN-01 in treating patients who have advanced or refractory solid tumors. |
| NCT00004059 ↗ | Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors | Completed | Memorial Sloan Kettering Cancer Center | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. UCN-01 may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of fluorouracil plus UCN-01 in treating patients who have advanced or refractory solid tumors. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Staurosporine
Condition Name
Clinical Trial Locations for Staurosporine
Trials by Country
Clinical Trial Progress for Staurosporine
Clinical Trial Phase
Clinical Trial Sponsors for Staurosporine
Sponsor Name
